I3F Stock Overview
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Infinity Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.016 |
| 52 Week High | US$0.016 |
| 52 Week Low | US$0.016 |
| Beta | 1.64 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| I3F | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | 2.0% |
| 1Y | n/a | -24.4% | 2.0% |
Return vs Industry: Insufficient data to determine how I3F performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how I3F performed against the German Market.
Price Volatility
| I3F volatility | |
|---|---|
| I3F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: I3F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine I3F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 30 | Seth Tasker | www.infi.com |
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company’s product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc. Fundamentals Summary
| I3F fundamental statistics | |
|---|---|
| Market cap | €234.87k |
| Earnings (TTM) | -€37.18m |
| Revenue (TTM) | €2.33m |
0.1x
P/S Ratio0.0x
P/E RatioIs I3F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I3F income statement (TTM) | |
|---|---|
| Revenue | US$2.57m |
| Cost of Revenue | US$28.53m |
| Gross Profit | -US$25.96m |
| Other Expenses | US$14.99m |
| Earnings | -US$40.95m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | -1,010.35% |
| Net Profit Margin | -1,593.93% |
| Debt/Equity Ratio | 0% |
How did I3F perform over the long term?
See historical performance and comparison